A team led by researchers from UCSF and Yale has found that half of people newly infected with HIV experience neurologic issues. These neurologic findings are generally not severe and usually resolve after participants started anti-retroviral therapy.
"We were surprised that neurologic findings were so pervasive in participants diagnosed with very recent HIV infection," said study lead author, Joanna Hellmuth, MD, MHS, clinical fellow in UCSF's Department of Neurology. "While the findings were mild, it is clear that HIV affects the nervous system within days of infection. Since the majority of these neurologic issues were resolved with treatment, our study reinforces recommendations that people at risk for HIV test often and start antiretroviral treatment immediately if they are infected."
The research will be published in the June 10, 2016, issue of Neurology, the medical journal of the American Academy of Neurology.
The team examined 139 participants in the RV254 Thai cohort who were recently infected with HIV. The time from infection to entry into the study ranged from 3 to 56 days with a median of 19 days. At this stage, participants would not test positive on the common antibody tests for HIV since they have not been infected long enough for a robust specific immune response to take place. Fifty-three percent had neurologic findings, with a third experiencing cognitive deficits, a quarter having motor issues, and nearly 20 percent experiencing neuropathy. Many experienced more than one symptom. One participant was diagnosed with Guillain-Barré Syndrome, the only severe case found in the cohort.
"In the early days of the epidemic in San Francisco, approximately 10 percent of patients with recent HIV infection presented with dramatic neurological disease. But that was likely due to patients coming in early because of the severity of symptoms they were experiencing. The Thai cohort has given us an opportunity to look at a broad range of newly infected patients, analyze their neurological functioning systematically and follow them over time. We are gaining deeper insights into the degree to which early HIV affects the nervous system," said study senior author, Serena Spudich, MD, Yale associate professor of neurology.
All participants were offered and commenced antiretroviral treatment at diagnosis. Ninety percent of the issues present at diagnosis were resolved after one month of treatment, but 9 percent of the participants had neurologic symptoms that were still not resolved six months after starting therapy. In addition, neurological symptoms were associated with higher levels of HIV found in participants' blood.
The study participants underwent extensive neurologic assessments. Self reported symptoms were correlated with objective neuropsychological testing. In addition, a quarter of participants opted to undergo a lumbar puncture and almost half of the patients agreed to undergo a MRI.
"This is one of the first comprehensive studies scrutinizing the involvement of the nervous system in early infection. Since we have been able to maintain the cohort for five years now, we will be able to study whether there are any persistent abnormalities that need to be addressed. Additionally, the ubiquity of symptoms in early infection found in this study reinforces the need for the brain to be considered as a compartment containing latent HIV as we design cure studies," said study co-author, Victor Valcour, MD, PhD, UCSF professor of neurology.
UCSF researchers collaborate on this study with the Thai Red Cross AIDS Research Centre and the U.S. Military HIV Research Program. The study's co-authors include James L. K. Fletcher, BMBCh, Eugène Kroon, MD, Jintana Intasan, BNS, Suwanna Puttamaswin, BNS, Nittaya Phanuphak, MD, PhD, Peeriya Prueksakaew, BNS, from the Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Jintanat Ananworanich, MD, PhD, Shelly J. Krebs, PhD, Bonnie Slike, MSc, and Linda L. Jagodzinski, PhD, from the U.S. Military HIV Research Program, Walter Reed Army Institute of Research; Sukalaya Lerdlum, MD, Mantana Pothisri, BSc, from Chulalongkorn University, Bangkok, Thailand; and Jared Narvid, MD, and Isabel Allen, PhD, from UCSF.
This work was supported by NIH/NIMH grants R01MH095613, R01NS061696, R21MH086341, as well as the US Military HIV Research Program, with added support from the National Institutes of Mental Health. The following organizations provided antiretroviral therapy: tenofovir, lamivudine, efavirenz by the Thai Government Pharmaceutical Organization; emtricitabine/tenofovir and emtricitabine/tenofovir/efavirenz by Gilead; efavirenz and raltegravir by Merck; and maraviroc was provided by ViiV Healthcare.
UCSF is the nation's leading university exclusively focused on health. Now celebrating the 150th anniversary of its founding as a medical college, UCSF is dedicated to transforming health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with world-renowned programs in the biological sciences, a preeminent biomedical research enterprise and top-tier hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals. Please visit http://www.ucsf.edu.